Why the study?
Does oxprenolol-based treatment reduce myocardial infarction, sudden cardiac death, and cerebrovascular accidents in men and women aged 40-64 years with uncomplicated essential hypertension?
Population
6357 men and women aged 40-64 years with uncomplicated essential hypertension
Comparison
Treatment based on a beta-blocker, with… vs Placebo replacing oxprenolol, with supplementary…
Design
RCT, randomized, double-blind
Follow-up
3-5 years
Authors
Loading...
Oxprenolol offers no cardiovascular event reduction in uncomplicated hypertension despite BP lowering; challenges beta-blocker outcome benefits beyond pressure control.
Does oxprenolol-based treatment reduce myocardial infarction, sudden cardiac death, and cerebrovascular accidents in men and women aged 40-64 years with uncomplicated essential hypertension?
Oxprenolol-based therapy did not significantly reduce sudden death, myocardial infarction, or cerebrovascular accidents compared to placebo in patients with uncomplicated essential hypertension, despite improving blood pressure control.
The IPPPSH Collaborative Group (1985) studied this question.